-
Tytuł:
-
Outcomes of head and neck cancer management from two cancer centres in Southern and Northern Europe during the first wave of COVID-19.
-
Autorzy:
-
Tagliabue M; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.; Department of Biomedical Sciences, University of Sassari, Sassari, Italy.
Russell B; Faculty of Life Sciences and Medicine, Translational Oncology & Urology Research (TOUR), King's College London, London, UK.
Moss C; Faculty of Life Sciences and Medicine, Translational Oncology & Urology Research (TOUR), King's College London, London, UK.
De Berardinis R; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
Chu F; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
Jeannon JP; Head, Neck and Thyroid Oncology Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
Pietrobon G; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
Haire A; Faculty of Life Sciences and Medicine, Translational Oncology & Urology Research (TOUR), King's College London, London, UK.
Grosso E; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
Wylie H; Faculty of Life Sciences and Medicine, Translational Oncology & Urology Research (TOUR), King's College London, London, UK.
Zorzi S; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
Proh M; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
Brunet-Garcia A; Head, Neck and Thyroid Oncology Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
Cattaneo A; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
Oakley R; Head, Neck and Thyroid Oncology Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
De Benedetto L; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
Arora A; Head, Neck and Thyroid Oncology Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
Riccio S; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
Fry A; Head, Neck and Thyroid Oncology Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
Bruschini R; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
Townley W; Head, Neck and Thyroid Oncology Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
Giugliano G; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
Orfaniotis G; Head, Neck and Thyroid Oncology Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
Madini M; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
Dolly S; Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Borghi E; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
Aprile D; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
Zurlo V; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
Bibiano D; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
Mastrilli F; Medical Administration, CMO, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Chiocca S; Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.
Van Hemelrijck M; Faculty of Life Sciences and Medicine, Translational Oncology & Urology Research (TOUR), King's College London, London, UK.
Gandini S; Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.
Simo R; Head, Neck and Thyroid Oncology Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK.
Ansarin M; Division of Otolaryngology and Head and Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy.
-
Źródło:
-
Tumori [Tumori] 2022 Jun; Vol. 108 (3), pp. 230-239. Date of Electronic Publication: 2021 Apr 12.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: 2018- : Thousand Oaks, CA : Sage Publications
Original Publication: Milano : Istituto nazionale per lo studio e la cura dei tumori
-
MeSH Terms:
-
COVID-19*/epidemiology
Head and Neck Neoplasms*/epidemiology
Head and Neck Neoplasms*/therapy
Aged ; Europe/epidemiology ; Humans ; Male ; Pandemics ; Retrospective Studies
-
Contributed Indexing:
-
Keywords: ACE inhibitors; COVID-19; head and neck cancer; postoperative complication; surgical outcomes
-
Entry Date(s):
-
Date Created: 20210413 Date Completed: 20220602 Latest Revision: 20220602
-
Update Code:
-
20240105
-
DOI:
-
10.1177/03008916211007927
-
PMID:
-
33845703
-
Objective: To describe the approach and outcomes from two cancer centres in Southern and Northern Europe during the first wave of coronavirus disease 2019 (COVID-19) of patients with head and neck cancer (HNC).
Methods: Data collection was performed on a retrospective cohort of patients surgically treated for primary HNC between March and May 2020, using data from two tertiary hospitals: the European Institute of Oncology (Milan) and Guy's & St Thomas' NHS Foundation Trust (London).
Results: We included 77 patients with HNC. More patients with COVID-19 were taking angiotensin-converting enzyme (ACE) inhibitors and had Clavien-Dindo Classification grade I compared to negative patients, respectively (60% vs 22% [ p = 0.058] and 40% vs 8% [ p = 0.025]). Multivariate logistic regression analyses confirmed our data ( p = 0.05 and 0.03, respectively). Sex and age were statistically significantly different ( p = 0.05 and <0.001 respectively), showing more male patients (75% vs 53.66%, respectively) and more elderly patients in Italy than in the United Kingdom (patients aged >63 years: 69.44% vs 29.27%).
Conclusions: This study presents a large cohort of patients with HNC with nasopharyngeal swab during the first peak of the COVID-19 pandemic in Europe. Patients with HNC with COVID-19 appeared more likely to develop postsurgical complications and to be taking ACE inhibitors. The preventive measures adopted guaranteed the continuation of therapeutic surgical intervention.